Among sensitizers of CTL killing—which are of particular therapeutic interest as they bear the potential to enhance anti-tumor immunity in PDA upon inhibition—were the previously described genes Adar and Cflar22–24, as well as Vps4b and Rnf31 (Fig. 2b, d). The gene discussed is RNF31; the disease is Patent ductus arteriosus.